Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2010

01.03.2010 | Bone and Soft Tissue Sarcomas

Differential Presentations, Clinical Courses, and Survivals of Osteosarcomas of the Proximal Humerus over Other Extremity Locations

verfasst von: Wan Hyeong Cho, MD, Won Seok Song, MD, Dae-Geun Jeon, MD, Chang-Bae Kong, MD, Min Suk Kim, MD, Jun Ah Lee, MD, Ji Young Yoo, MD, Jae Do Kim, MD, Soo-Yong Lee, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Although there are controversies about the prognosis of proximal humeral osteosarcoma, our previous study showed poor survival in those patients. In the present study, we undertook to determine why this site is associated with a poor outcome and to identify the clinicopathologic variables involved.

Methods

The study cohort consisted of 36 proximal humeral and 341 other extremity American Joint Committee on Cancer (AJCC) stage II osteosarcomas. We examined the clinicopathologic differences between these osteosarcomas. The prognostic significances of factors identified for a proximal humoral location were evaluated by survival analysis of all 377 patients.

Results

Patients with a proximal humeral osteosarcoma had the following characteristics: a higher incidence of pathologic fracture (P < 0.01), an osteolytic pattern on plain radiographs (P < 0.01), an unusual pathological subtype (P = 0.01), poor histologic response (P < 0.01), and an increased tumor-volume ratio (TVR) (P < 0.01). Multivariate analysis revealed that a large tumor volume (P < 0.01), an increase in tumor volume (P < 0.01), and a poor histologic response to preoperative chemotherapy (P < 0.01) independently predicted shorter metastasis-free survival.

Conclusions

The association between proximal humeral osteosarcoma and poor survival could be the result of unresponsiveness to chemotherapy, which was expressed by a tumor volume increase in our patients.
Literatur
1.
Zurück zum Zitat Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.CrossRefPubMed Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.CrossRefPubMed
2.
Zurück zum Zitat Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res. 2002;391:53–61.CrossRef Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res. 2002;391:53–61.CrossRef
3.
Zurück zum Zitat Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–58.PubMed Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–58.PubMed
4.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.CrossRefPubMed Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.CrossRefPubMed
5.
Zurück zum Zitat Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, Versari M. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90:478–84.PubMed Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, Versari M. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90:478–84.PubMed
6.
Zurück zum Zitat Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002;9:171–5.PubMed Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002;9:171–5.PubMed
7.
Zurück zum Zitat Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423–31.PubMed Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423–31.PubMed
8.
Zurück zum Zitat Kim MS, Lee SY, Cho WH, et al. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J Orthop Sci. 2009;14:292–7.CrossRefPubMed Kim MS, Lee SY, Cho WH, et al. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J Orthop Sci. 2009;14:292–7.CrossRefPubMed
9.
Zurück zum Zitat Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand. 1998;69:230–36.PubMed Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand. 1998;69:230–36.PubMed
10.
Zurück zum Zitat Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: A systematic review. Eur J Surg Oncol. 2009; [Epub ahead of print]. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: A systematic review. Eur J Surg Oncol. 2009; [Epub ahead of print].
11.
Zurück zum Zitat Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20:955–60.CrossRefPubMed Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20:955–60.CrossRefPubMed
12.
Zurück zum Zitat Kim MS, Lee SY, Cho WH, et al. An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients. J Surg Oncol. 2008;98:427–31.CrossRefPubMed Kim MS, Lee SY, Cho WH, et al. An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients. J Surg Oncol. 2008;98:427–31.CrossRefPubMed
13.
Zurück zum Zitat Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res. 2007;463:157–65.PubMed Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res. 2007;463:157–65.PubMed
14.
Zurück zum Zitat Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed
15.
Zurück zum Zitat Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55–67.CrossRefPubMed Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55–67.CrossRefPubMed
16.
Zurück zum Zitat Kim MS, Lee SY, Cho WH, et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol. 2008;15:906–14.CrossRefPubMed Kim MS, Lee SY, Cho WH, et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol. 2008;15:906–14.CrossRefPubMed
17.
Zurück zum Zitat Gobel V, Jurgens H, Etspuler G, Kemperdick H, Jungblut RM, Stienen U, et al. Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113:187–91.CrossRefPubMed Gobel V, Jurgens H, Etspuler G, Kemperdick H, Jungblut RM, Stienen U, et al. Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113:187–91.CrossRefPubMed
18.
Zurück zum Zitat Holscher HC, Bloem JL, Vanel D, Hermans J, Nooy MA, Taminiau AH, et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. Radiology. 1992;182:839–44.PubMed Holscher HC, Bloem JL, Vanel D, Hermans J, Nooy MA, Taminiau AH, et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. Radiology. 1992;182:839–44.PubMed
19.
Zurück zum Zitat Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer. 1998;82:851–9.CrossRefPubMed Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer. 1998;82:851–9.CrossRefPubMed
20.
Zurück zum Zitat Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003;21:334–41.CrossRefPubMed Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003;21:334–41.CrossRefPubMed
21.
Zurück zum Zitat Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer. 2002;94:1069–77.CrossRefPubMed Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer. 2002;94:1069–77.CrossRefPubMed
22.
Zurück zum Zitat Fuchs B, Hoekzema N, Larson DR, Inwards CY, Sim FH. Osteosarcoma of the pelvis: outcome analysis of surgical treatment. Clin Orthop Relat Res. 2009;467:510–8.CrossRefPubMed Fuchs B, Hoekzema N, Larson DR, Inwards CY, Sim FH. Osteosarcoma of the pelvis: outcome analysis of surgical treatment. Clin Orthop Relat Res. 2009;467:510–8.CrossRefPubMed
23.
Zurück zum Zitat Lawrence JA, Babyn PS, Chan HS, Thorner PS, Pron GE, Krajbich IJ. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology. 1993;189:43–7.PubMed Lawrence JA, Babyn PS, Chan HS, Thorner PS, Pron GE, Krajbich IJ. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology. 1993;189:43–7.PubMed
24.
Zurück zum Zitat Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res. 2000;376:200–8.CrossRefPubMed Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res. 2000;376:200–8.CrossRefPubMed
25.
Zurück zum Zitat Kim MS, Lee SY, Lee TR, et al. Prognosticjeon effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute. J Surg Oncol. 2009;100:233–9.CrossRefPubMed Kim MS, Lee SY, Lee TR, et al. Prognosticjeon effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute. J Surg Oncol. 2009;100:233–9.CrossRefPubMed
26.
Zurück zum Zitat Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer. 2007;43:1944–51.CrossRefPubMed Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer. 2007;43:1944–51.CrossRefPubMed
27.
Zurück zum Zitat Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma : prognostic importance and treatment implications. J Bone Joint Surg Am. 2002;84-A:49–57.PubMed Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma : prognostic importance and treatment implications. J Bone Joint Surg Am. 2002;84-A:49–57.PubMed
28.
Zurück zum Zitat Bacci G, Ferrari S, Longhi A, et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand. 2003;74:449–54.PubMedCrossRef Bacci G, Ferrari S, Longhi A, et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand. 2003;74:449–54.PubMedCrossRef
Metadaten
Titel
Differential Presentations, Clinical Courses, and Survivals of Osteosarcomas of the Proximal Humerus over Other Extremity Locations
verfasst von
Wan Hyeong Cho, MD
Won Seok Song, MD
Dae-Geun Jeon, MD
Chang-Bae Kong, MD
Min Suk Kim, MD
Jun Ah Lee, MD
Ji Young Yoo, MD
Jae Do Kim, MD
Soo-Yong Lee, MD
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0825-6

Weitere Artikel der Ausgabe 3/2010

Annals of Surgical Oncology 3/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.